COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,785 Articles (22,523 medRxiv, 8,262 bioRxiv)

Most recent first Previous |  Page 1792: Articles 17911-17920  | Next

Towards a COVID-19 symptom triad: The importance of symptom constellations in the SARS-CoV-2 pandemic
Melms, L. E., Falk, E., Schieffer, B., Jerrentrup, A., Wagner, U., Matrood, S., Schaefer, J. R., Müller, T., Hirsch, M.
10.1101/2021.02.01.21250537 — Posted: 2021-02-03
Bayesian Calibration of Using CO2 Sensors to Assess Ventilation Conditions and Associated COVID-19 Airborne Aerosol Transmission Risk in Schools
Hou, D., Katal, A., Wang, L.
10.1101/2021.01.29.21250791 — Posted: 2021-02-03
Limited specificity of SARS-CoV-2 antigen-detecting rapid diagnostic tests at low temperatures
Haage, V. C., Moreira-Soto, A., Sacks, J. A., Corman, V. M., Drosten, C., Drexler, J. F.
10.1101/2021.02.01.21250904 — Posted: 2021-02-03
Returning to a normal life via COVID-19 vaccines in the USA: a large-scale agent-based simulation study
Li, J., Giabbanelli, P.
10.1101/2021.01.31.21250872 — Posted: 2021-02-03
Stay Home and Stay Active? The impact of stay-at-home restrictions on physical activity routines in the UK during the COVID-19 pandemic
Eshelby, V., Sogut, M., Jolly, K., Vlaev, I., Elliott, M. T.
10.1101/2021.01.31.21250863 — Posted: 2021-02-03
IN-HOSPITAL CONTINUATION WITH ANGIOTENSIN RECEPTOR BLOCKERS IS ASSOCIATED WITH A LOWER MORTALITY RATE THAN CONTINUATION WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN COVID-19 PATIENTS A RETROSPECTIVE COHORT STUDY
De Abajo, F. J., Rodriguez-Miguel, A., Rodriguez-Martin, S., Lerma, V., Garcia-Lledo, A., MED-ACE2-COVID19 Study Group
10.1101/2021.02.01.21250853 — Posted: 2021-02-03
The basis of a more contagious 501Y.V1 variant of SARS-COV-2
Zhang, G., Liu, H., Zhang, Q., Wei, P., Chen, Z., Aviszus, K., Yang, J., Downing, W., Peterson, S., Jiang, C., Liang, B., Reynoso, L., Downey, G., Frankel, S., Kapper, J., Marrack, P.
10.1101/2021.02.02.428884 — Posted: 2021-02-02
Computational insights into differential interaction of mamalian ACE2 with the SARS-CoV-2 spike receptor binding domain
Lupala, C. S., Kumar, V., Su, X.-d., Wu, C., Liu, H.
10.1101/2021.02.02.429327 — Posted: 2021-02-02
Evolution of ACE2 and SARS-CoV-2 Interplay Across 247 Vertebrates
Zhang, Z., Zhang, T., Wu, Q., Ma, Y., Liu, W., Zou, C.
10.1101/2021.01.28.428568 — Posted: 2021-02-02 Discussion: Onsite
Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
Noy-Porat, T., Mechaly, A., Levy, Y., Makdasi, E., Alcalay, R., Gur, D., Aftalion, M., Falach, R., Leviatan Ben-Arye, S., Lazar, S., Zauberman, A., Epstein, E., Chitlaru, T., Weiss, S., Achdout, H., Edgeworth, J. D., Kikkeri, R., Yu, H., Chen, X., Yitzhaki, S., Shapira, S. C., Padler-Karavani, V., Mazor, O., Rosenfeld, R.
10.1101/2021.02.02.428995 — Posted: 2021-02-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).